Mainz Biomed announced that London-based Marylebone Laboratory has introduced ColoAlert, Mainz Biomed’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer, or CRC, to its extensive UK and international customer base.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
- Mainz Biomed enters commercial partnership with Fugene Genetics for ColoAlert
- Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
- Mainz Biomed Secures up to $50M in New Funding
- Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain